Display options
Cite
Tse WF, Yang W, Huang W. A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. Clinicoecon Outcomes Res. 2015;7:431-9doi: 10.2147/CEOR.S85535.
Tse, W. F., Yang, W., & Huang, W. (2015). A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. ClinicoEconomics and outcomes research : CEOR, 7431-9. https://doi.org/10.2147/CEOR.S85535
Tse, Wah Fung, et al. "A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes." ClinicoEconomics and outcomes research : CEOR vol. 7 (2015): 431-9. doi: https://doi.org/10.2147/CEOR.S85535
Tse WF, Yang W, Huang W. A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. Clinicoecon Outcomes Res. 2015 Aug 11;7:431-9. doi: 10.2147/CEOR.S85535. eCollection 2015. PMID: 26316787; PMCID: PMC4540173.
Copy Download .nbib Format: NLM
Share it on

Clinicoecon Outcomes Res. 2015 Aug 11;7:431-9. doi: 10.2147/CEOR.S85535. eCollection 2015.

A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes.

ClinicoEconomics and outcomes research : CEOR

Wah Fung Tse, Weimin Yang, Wenlong Huang

Affiliations

  1. School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, People's Republic of China.
  2. Editorial Department of Journal of Nanjing University of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
  3. School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, People's Republic of China ; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China.

PMID: 26316787 PMCID: PMC4540173 DOI: 10.2147/CEOR.S85535

Abstract

BACKGROUND: Since its introduction in 1996, highly active antiretroviral therapy (HAART), which involves the combination of antiretroviral drugs, has resulted in significant improvements in the morbidity, mortality, and life expectancy of HIV-infected patients. Numerous studies of the cost-effectiveness of HAART from different perspectives in HIV have been reported.

AIM: To investigate the economic outcomes and relevance of HAART for people living with HIV.

MATERIALS AND METHODS: A narrative literature review was conducted on 22 peer-reviewed full economic evaluations of people living with HIV treated with different HAART regimens and published in English between January 2005 and December 2014. Information regarding study details, such as interventions, outcomes, and modeling methods, was extracted. The high heterogeneity of the included studies rendered a meta-analysis inappropriate; therefore, we conducted a comparative analysis of studies grouped according to the similarity of the different intervention types and outcomes.

RESULTS: Most of the economic evaluations of HAART focused on comparisons between the specific HAART regimens and others from the following perspectives: injecting drug users versus noninjecting drug users, HIV-infected adults without AIDS versus those with AIDS, regimens based on developed world guidelines versus those based on developing world guidelines, self-administered HAART versus directly observed HAART, and "ideal" versus "typical" regimens.

CONCLUSION: In general, HAART is more cost-effective than other therapeutic regimens adopted so far. Further investigations, especially head-to-head comparisons of "ideal" and "typical" trials of different regimen combinations, are required to identify the optimal HAART regimens.

Keywords: HAART; cost-effectiveness; narrative review

References

  1. Clinicoecon Outcomes Res. 2013 Oct 03;5:489-96 - PubMed
  2. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):631-4 - PubMed
  3. Ther Clin Risk Manag. 2012;8:377-84 - PubMed
  4. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):562-9 - PubMed
  5. Lancet. 2006 Aug 5;368(9534):531-6 - PubMed
  6. AIDS. 2010 Jul 31;24(12):1929-35 - PubMed
  7. J Formos Med Assoc. 2007 Aug;106(8):631-40 - PubMed
  8. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):91-100 - PubMed
  9. HIV Clin Trials. 2008 Jul-Aug;9(4):225-37 - PubMed
  10. Cost Eff Resour Alloc. 2007 Nov 22;5:15 - PubMed
  11. AIDS. 2006 Nov 14;20(17):2207-15 - PubMed
  12. AIDS Res Treat. 2012;2012:595762 - PubMed
  13. PLoS One. 2012;7(2):e30216 - PubMed
  14. Pharmacoeconomics. 2010;28 Suppl 1:147-67 - PubMed
  15. PLoS One. 2010 Apr 13;5(4):e10154 - PubMed
  16. Braz J Infect Dis. 2013 Jul-Aug;17(4):464-79 - PubMed
  17. PLoS One. 2013;8(2):e54180 - PubMed
  18. Pharmacoeconomics. 2010;28 Suppl 1:129-46 - PubMed
  19. Med Care. 2006 Oct;44(10):893-9 - PubMed
  20. JAMA. 1998 Mar 25;279(12):930-7 - PubMed
  21. Antivir Ther. 2006;11(1):63-72 - PubMed
  22. Appl Health Econ Health Policy. 2009;7(4):229-43 - PubMed
  23. Clinicoecon Outcomes Res. 2011;3:197-205 - PubMed
  24. PLoS Med. 2006 Jan;3(1):e4 - PubMed
  25. Jpn J Infect Dis. 2006 Jun;59(3):168-73 - PubMed
  26. Pharmacoeconomics. 2010;28 Suppl 1:83-105 - PubMed

Publication Types